Data / Drug companies / Exemestane
Exemestane: 12 companies and 12 products in the FDA NDC directory
Exemestane is listed in the FDA National Drug Code Directory by 12 companies, with 12 products in commercial distribution. 10 of the products (83.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, film coated; tablet, sugar coated, and the newest product started marketing on October 31, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 12
- Generic (ANDA) products
- 10 (83.3%)
- Application numbers
- 8
- Routes
- Oral
- Brand names
- Aromasin
- openFDA record search
- api.fda.gov
Companies that list exemestane
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Aurobindo Pharma Limited | 1 | tablet, film coated | Generic drugs (ANDA) | May 20, 2022 |
| Breckenridge Pharmaceutical, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | December 19, 2019 |
| Bryant Ranch Prepack | 1 | tablet, film coated | Generic drugs (ANDA) | December 19, 2019 |
| Cipla USA Inc. | 1 | tablet | Generic drugs (ANDA) | April 27, 2018 |
| Florida Pharmaceutical Products, LLC | 1 | tablet, film coated | Generic drugs (ANDA) | January 15, 2021 |
| Mylan Pharmaceuticals Inc. | 1 | tablet, sugar coated | Authorized generics (NDA) | April 1, 2011 |
| NorthStar RxLLC | 1 | tablet, film coated | Generic drugs (ANDA) | January 1, 2025 |
| Opko Pharmaceuticals, LLC | 1 | tablet, coated | Generic drugs (ANDA) | October 31, 2026 |
| Pharmacia & Upjohn Company LLC | 1 | tablet | New drug applications (NDA) | October 21, 1999 |
| Upsher-Smith Laboratories, LLC | 1 | tablet | Generic drugs (ANDA) | July 27, 2017 |
| Zydus Lifesciences Limited | 1 | tablet | Generic drugs (ANDA) | October 8, 2018 |
| Zydus Pharmaceuticals USA Inc. | 1 | tablet | Generic drugs (ANDA) | October 8, 2018 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 5 | 41.7% |
| Tablet, film coated | 5 | 41.7% |
| Tablet, sugar coated | 1 | 8.3% |
| Tablet, coated | 1 | 8.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 10 | 83.3% |
| Authorized generics (NDA) | 1 | 8.3% |
| New drug applications (NDA) | 1 | 8.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Aromatase Inhibitor | 12 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.